News
The latest news, selected media, press releases, scientific articles and literature review from Neurochlore.
Information note on the re-use of your health data
11 July 2022
Although the phase III clinical trial was a failure, Neurochlore was able to retrieve data that could be promising. Indeed, we are convinced that Bumetanide works on sub-populations, defined by more specific criteria that were...
Read More
IBEN hosts a satellite conference at FENS 2022
9 March 2022
IBEN will give a satellite conference at the FENS 2022, an european congress of neurosciences. The conference, which take place on July 7 and 8 at RIVE Montparnasse, will focus on the Neuroarcheology of the...
Read More
The first 1000 days, based on the work of Yehezkel Ben-Ari
23 September 2021
Short video depicting the hypothesis that autism and developmental disorders are generated in utero and how identification of the alterations they produce will enable their early prediction and novel treatments. https://www.youtube.com/watch?v=qR-yb-mSh8I
Read More
Servier and Neurochlore announce the main results of the two phase 3 clinical studies assessing bumetanide in the treatment of Autism Spectrum Disorders in children and adolescents
10 September 2021
PR-Servier-Neurochlore-Bumetanide Phase 3 ResultsTélécharger
Read More
Smaller brain volumes after birth by Cesarean Section
24 March 2021
Being born is not easy. Mammals need to pass through the birth canal before coming out into this world, and to do so the head (and whole body) undergoes a harsh squeezing. Thankfully, the newborn...
Read More
Sleeping pills that cause “awakenings”?
17 February 2021
How is it possible that drugs used to sedate or calm people, called Benzodiazepines, can induce transient awakenings in comatose patients? In our latest Commentary in Translational Medicine Communications Yehezkel Ben-Ari hypothesizes that a dysregulation...
Read More
A new report on the promising use of Bumetanide treatment for autism
24 January 2021
Since our groundbreaking positive results on the use of Bumetanide (a highly selective antagonist of the NKCC1 chloride importer) to treat autism, first in a pilot open trial and then in two double-blind clinical trials,...
Read More
A Huntington’s disease study supporting the Neuroarcheology concept
16 August 2020
Huntington’s disease, a dominant heritable disease that manifests in mid-adulthood, is caused by expansion of a polyglutamine tract within the huntingtin protein (HTT). The mutation leading to the polyglutamine tract confers a toxic gain of...
Read More
The GABA developmental sequence is altered in a mouse model of Rett Syndrome
26 June 2019
The activity of the neurotransmitter GABA, the main inhibitory transmitter in the brain, follows a developmental sequence. In early development GABA excites neurons via type A GABA receptors (GABAAR), and later it inhibits them. In...
Read More
No stop-growing signal around birth in a rodent model of autism
24 January 2019
How does the brain prepare for birth? Several indirect lines of evidence in Humans suggest that the velocity at which the brain grows in utero slows down during the third trimester, a process that will...
Read More
Immune activation during gestation leads to hippocampal neuronal alterations already at birth
4 November 2018
Two of the most biologically complex and vulnerable periods are pregnancy and birth. Birth is a stressful event with a release of several stress molecules needed to facilitate the transition of the fetus to extrauterine...
Read More
A promising multicenter trial to alleviate autistic disorders
14 March 2017
In animal models of autism spectrum disorder (ASD), the NKCC1 chloride-importer inhibitor bumetanide restores physiological (Cl−)i levels, enhances GABAergic inhibition and attenuates electrical and behavioral symptoms of ASD. In an earlier phase 2 trial; bumetanide...
Read More
4e Prize Créa13 2014 : Neurochlore
10 November 2014
Encourage, support and publicize active, innovative companies that create jobs in the industrial and craft fields, these are the objectives set by the General Council of Bouches-du-Rhône, which has been organizing the Créa 13 prize...
Read More
The diuretic Bumetanide and the birth hormone Oxytocin point to a common pathway in the early pathogenesis of Autism in rodents
26 February 2014
The scientific community agrees on the early origin – fetal and/or early postnatal – of autism. The teams of Yehezkel Ben-Ari (CEO of Neurochlore and Emeritus Research Director at Inserm) at Neurochlore and at the...
Read More
Economics Trophies: 1st prize in the category: “Tremplins La Provence”
14 November 2013
Voir la page de l'article de La Provence
Read More
Treating Fragile X syndrome with the diuretic bumetanide: a case report
10 June 2013
We report that daily administration of the diuretic NKCC1 chloride co-transporter, bumetanide, reduces the severity of autism in a 10-year-old Fragile X boy using CARS, ADOS, ABC, RDEG and RRB before and after treatment. In...
Read More
A randomised controlled trial of bumetanide in the treatment of autism in children
11 December 2012
Gamma aminobutyric acid (GABA)-mediated synapses and the oscillations they orchestrate are altered in autism. GABA-acting benzodiazepines exert in some patients with autism paradoxical effects, raising the possibility that like in epilepsies, GABA excites neurons because...
Read More
The GABA excitatory/inhibitory shift in brain maturation and neurological disorders
18 October 2012
Ionic currents and the network-driven patterns they generate differ in immature and adult neurons: The developing brain is not a "small adult brain." One of the most investigated examples is the developmentally regulated shift of...
Read More